&lt;p&gt;Long Non-Coding RNAs in Drug Resistance of Breast Cancer&lt;/p&gt;

Du, Tonghua; Shi, Ying; Xu, Shengnan; Wang, Xiaoyu; Sun, Haiyin; Liu, Bin

doi:10.2147/ott.s255226

Cited by 23 publications

(9 citation statements)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Downregulation of CASC2 and CDK19 increased PTX sensitivity in vitro and inhibited tumor growth in vivo [ 110 ]. Given this information, the exact mechanism of CASC2-mediated PTX resistance remains unknown but is shown to be actuated by interactions with miR-18a-5p that regulate CDK19 ([ 110 ] and reviewed in [ 111 ]). Loss of miR-17 and miR-20b confers Taxol resistance in breast cancer by enhancing expression of nuclear receptor coactivator 3 (NCOA3) [ 112 ], which is significantly upregulated in Taxol-resistant breast cancer cells.…”

Section: Taxane Resistance In Breast Cancermentioning

confidence: 99%

Mechanisms of Taxane Resistance

Maloney

Hoover

Morejon-Lasso

et al. 2020

Cancers

120

View full text Add to dashboard Cite

The taxane family of chemotherapy drugs has been used to treat a variety of mostly epithelial-derived tumors and remain the first-line treatment for some cancers. Despite the improved survival time and reduction of tumor size observed in some patients, many have no response to the drugs or develop resistance over time. Taxane resistance is multi-faceted and involves multiple pathways in proliferation, apoptosis, metabolism, and the transport of foreign substances. In this review, we dive deeper into hypothesized resistance mechanisms from research during the last decade, with a focus on the cancer types that use taxanes as first-line treatment but frequently develop resistance to them. Furthermore, we will discuss current clinical inhibitors and those yet to be approved that target key pathways or proteins and aim to reverse resistance in combination with taxanes or individually. Lastly, we will highlight taxane response biomarkers, specific genes with monitored expression and correlated with response to taxanes, mentioning those currently being used and those that should be adopted. The future directions of taxanes involve more personalized approaches to treatment by tailoring drug–inhibitor combinations or alternatives depending on levels of resistance biomarkers. We hope that this review will identify gaps in knowledge surrounding taxane resistance that future research or clinical trials can overcome.

show abstract

Section: Taxane Resistance In Breast Cancermentioning

confidence: 99%

Mechanisms of Taxane Resistance

Maloney

Hoover

Morejon-Lasso

et al. 2020

Cancers

120

View full text Add to dashboard Cite

show abstract

“…ncRNAs are accountable for chemoresistance (Figure 2) as they play a part in (1) moderating drug resistance related genes, (2) affecting intracellular drug concentration, (3) initiating alternative signalling pathway, (4) promoting EMT, (5) altering drug efficiency by blocking DNA damage response, (6) preventing therapeutic-induced cell death and (7) altering cell cycle [22,166,167]. In general, ncRNAs contribute to chemoresistance in different cancers [168], such as gastric cancers [169,170], pancreatic cancers [171,172], breast cancers [173,174], glioblastomas [175,176], hepatocellular carcinomas [177,178], lung cancers [179,180], leukaemias [181,182] and ovarian cancers [183,184], among others. Despite all these cancers, the following sections will focus on how ncRNAs are involved in chemoresistance arising in CRC.…”

Section: Ncrnas In Chemotherapeutic Resistancementioning

confidence: 99%

The Mechanistic Roles of ncRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer

Micallef

Baron

2021

ncRNA

View full text Add to dashboard Cite

Colorectal Cancer (CRC) is one of the most common gastrointestinal malignancies which has quite a high mortality rate. Despite the advances made in CRC treatment, effective therapy is still quite challenging, particularly due to resistance arising throughout the treatment regimen. Several studies have been carried out to identify CRC chemoresistance mechanisms, with research showing different signalling pathways, certain ATP binding cassette (ABC) transporters and epithelial mesenchymal transition (EMT), among others to be responsible for the failure of CRC chemotherapies. In the last decade, it has become increasingly evident that certain non-coding RNA (ncRNA) families are involved in chemoresistance. Research investigations have demonstrated that dysregulation of microRNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) contribute towards promoting resistance in CRC via different mechanisms. Considering the currently available data on this phenomenon, a better understanding of how these ncRNAs participate in chemoresistance can lead to suitable solutions to overcome this problem in CRC. This review will first focus on discussing the different mechanisms of CRC resistance identified so far. The focus will then shift onto the roles of miRNAs, lncRNAs and circRNAs in promoting 5-fluorouracil (5-FU), oxaliplatin (OXA), cisplatin and doxorubicin (DOX) resistance in CRC, specifically using ncRNAs which have been recently identified and validated under in vivo or in vitro conditions.

show abstract

“…Currently, mounting evidences have demonstrated that lncRNAs and mRNAs played critical roles in various physiological processes, such as cell activity, gene regulation, and so on ( Fukushima and Kida, 2019 ; De Troyer et al, 2020 ; Labonté et al, 2020 ). Therefore, dissecting how lncRNAs regulate tumor progress attracts great interest from researchers ( Majidinia and Yousefi, 2020 ). In breast cancer (BRCA), high levels of BCRT1, SPRY4-IT1, RP11-19E11, and FAM83H-AS1 were associated with clinical stage and prognosis ( Giro-Perafita et al, 2020 ; Han et al, 2020 ; Liang et al, 2020 ; Song et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Identification of Key lncRNA–mRNA Pairs and Functional lncRNAs in Breast Cancer by Integrative Analysis of TCGA Data

Zheng

Chen

et al. 2021

Front. Genet.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) play an important role in many diseases and are involved in the post-transcriptional regulatory network of tumors. The purpose of this study is to mine new lncRNA–mRNA regulatory pairs and analyze the new mechanism of lncRNA involvement in breast cancer progression. Using breast cancer miRNA and mRNA expression profiling from The Cancer Genome Atlas (TCGA), we identified 59 differentially expressed lncRNAs, 88 differentially expressed miRNAs, and 1,465 differentially expressed mRNAs between breast cancer tissue and adjacent normal breast cancer. Whereafter, four candidate lncRNAs (FGF14-AS2, LINC01235, AC055854.1, and AC124798.1) were identified by the Kaplan–Meier (K–M) plotter. Furthermore, we screened the hub lncRNA (LINC01235) through univariate Cox analysis, multivariate Cox analysis, and qPCR validation, which was significantly correlated with breast cancer stage, ER status, and pathological N. Subsequently, 107 LINC01235-related mRNAs were obtained by combining differentially expressed miRNAs, differentially expressed mRNAs, and LINC01235 targeting miRNAs and mRNAs. The protein–protein interaction (PPI) network was established by Cytoscape software, and 53 key genes were screened. Function and pathway enrichment showed that LINC01235-related key genes might be involved in the process of cell differentiation, cell proliferation, and p53 signal pathway. In addition, LINC01235 has been confirmed to regulate the proliferation, migration, and invasion of MCF-7 cells in in vitro experiments. Furthermore, we screened three mRNAs (ESR1, ADRA2A, and DTL) associated with breast cancer drug resistance from key genes. Through RNA interference experiments in vitro and correlation analysis, we found that there was a negative feedback mechanism between LINC01235 and ESR1/ADRA2A. In conclusion, our results suggest that LINC01235-ESR1 and LINC01235-ADRA2A could serve as important co-expression pairs in the progression of breast cancer, and LINC01235 plays a key role as an independent prognostic factor in patients with breast cancer. The findings of this work greatly increase our understanding of the molecular regulatory mechanisms of lncRNA in breast cancer.

show abstract

<p>Long Non-Coding RNAs in Drug Resistance of Breast Cancer</p>

Cited by 23 publications

References 131 publications

Mechanisms of Taxane Resistance

Mechanisms of Taxane Resistance

The Mechanistic Roles of ncRNAs in Promoting and Supporting Chemoresistance of Colorectal Cancer

Identification of Key lncRNA–mRNA Pairs and Functional lncRNAs in Breast Cancer by Integrative Analysis of TCGA Data

Contact Info

Product

Resources

About